The inclusion of flow cytometric evaluation assays during pre-clinical drug development has increased and enhanced the detail of data generated to support the safety and efficacy of new biopharmaceuticals. Identifying harmful side effects in new drugs (toxicology) early in the development process is as important to drug companies as are studies that confirm a drug’s efficacy.  Identifying the parameters that would reject a compound early in the development process can save drug companies tens, if not hundreds, of millions of dollars.

FlowMetric’s pre-clinical development services have been developed to make drug discovery faster and more effective. Partnering with FlowMetric gives clients flexible access to the latest tools for lead candidate validation and proof-of-concept studies. FlowMetric can help test new drug candidates for possible adverse effects on or assist in obtaining FDA approval (regulatory study) for drug candidates.

FlowMetric offers extensive flow cytometry analysis that supports pre-clinical drug development including:

Immunophenotyping
Peripheral blood cross-reactivity
Binding activity
Stability and cell receptor dynamics

FlowMetric’s pre-clinical drug development process  supports the identification and characterization of both cell morphology and function, and helps identify observed alterations as intended or unexpected effects of new biopharmaceutical entities.